Similarly, patients with G3 residual tumors had worse DFS (HR= 3.395, p=0.011) than patients with G1/G2 tumors, and patients with small tumor size had more favorable outcome compared to the greater tumour sizes (HR 0.450, p=0.021 for ypT1/2 vs ypT3/4) (Table 6). The gene discussed is RAB1A; the disease is neoplasm.